Heart Disease, Infections, Technology / 07.05.2024
ESCMID: Basel Scientists Developing Breath Test for Antibiotic Monitoring
MedicalResearch.com Interview with:
[caption id="attachment_61647" align="alignleft" width="125"]
Dr. Dräger[/caption]
Sarah Dräger, MD
Postdoc, BRCCH Researcher
Internal Medicine and ID specialist
Division of Internal Medicine
University Hospital Basel, Switzerland
Basel
MedicalResearch.com: What is the background for this study?
Response:In patients with severe infections and patients in the intensive care unit, therapeutic drug monitoring (TDM) may be used to optimize and personalize intravenous antibiotic treatment. In these patients, “conventional antibiotic dosing”, e.g. selection of the dose only considering the renal function and, if applicable, body weight, may lead to over- or underdosing due to an altered drug metabolism. This, in turn may be associated with worse clinical outcome or toxic side effects.
TDM is used to monitor antibiotic blood plasma concentrations and provides guidance to the clinicians to adjust the antibiotic dosing according to the TDM results. But the collection of blood is an invasive, time- and resource-consuming sample collection technique and leads to discomfort to the patients. Additionally, turnaround time may be long (3h to 8h), and analyses may be offered only twice or three time a week. This may be too late to guide antibiotic dosing timely in patients with a very dynamic drug metabolism. Therefore, alternatives are required to overcome the limitations of current TDM.
By using exhaled breath, we aim to develop an innovative therapeutic drug monitoring technique, which is non-invasive, easy to collect, not associated with discomfort to the patient, and which may allow to decrease the turnaround time, especially when combined with real-time analyses.
Dr. Dräger[/caption]
Sarah Dräger, MD
Postdoc, BRCCH Researcher
Internal Medicine and ID specialist
Division of Internal Medicine
University Hospital Basel, Switzerland
Basel
MedicalResearch.com: What is the background for this study?
Response:In patients with severe infections and patients in the intensive care unit, therapeutic drug monitoring (TDM) may be used to optimize and personalize intravenous antibiotic treatment. In these patients, “conventional antibiotic dosing”, e.g. selection of the dose only considering the renal function and, if applicable, body weight, may lead to over- or underdosing due to an altered drug metabolism. This, in turn may be associated with worse clinical outcome or toxic side effects.
TDM is used to monitor antibiotic blood plasma concentrations and provides guidance to the clinicians to adjust the antibiotic dosing according to the TDM results. But the collection of blood is an invasive, time- and resource-consuming sample collection technique and leads to discomfort to the patients. Additionally, turnaround time may be long (3h to 8h), and analyses may be offered only twice or three time a week. This may be too late to guide antibiotic dosing timely in patients with a very dynamic drug metabolism. Therefore, alternatives are required to overcome the limitations of current TDM.
By using exhaled breath, we aim to develop an innovative therapeutic drug monitoring technique, which is non-invasive, easy to collect, not associated with discomfort to the patient, and which may allow to decrease the turnaround time, especially when combined with real-time analyses.
Prof. Mainelis[/caption]
Gediminas "Gedi" Mainelis, Ph.D.
Professor, Department of Environmental Sciences
School of Environmental and Biological Sciences
Rutgers, The State University of New Jersey
MedicalResearch.com: What is the background for this study? What types of particles, ie where do they come from?
Response: This work is a continuation of my research on nanoparticles in consumer products. We have investigated and published on the release of particles from nano-enabled consumer products, such as cosmetic powders, various sprays and clothing.
In this project, we were interested in potential resuspension of particles once nano-enabled consumer sprays are used. The particles are added into consumer products to provide them certain desired properties, like antimicrobial protection, odor reduction or protection against UV (sunscreen). Once the products are used, the particles are released and we could be exposed to them.
Dr. Li Gan[/caption]
Dr. Li Gan PhD
Burton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Diseases
Brain and Mind Research Institute
Weill Cornell Medical College
[caption id="attachment_61627" align="alignleft" width="150"]

Dr. Thomas Robert[/caption]
MedicalResearch.com Interview with:
Thomas Robert, MD, AIX
Associate Professor of Nephrology
APHM (Assistance Publique - Hopitaux de Marseille)
Marseille, Provence-Alpes-Côte d'Azur, France
[caption id="attachment_61498" align="alignleft" width="132"]
Dr. Letavernier[/caption]
Prof. Emmanuel Letavernier, MD PhD
Nephrologist at Tenon Hospital
Paris, France
MedicalResearch.com: What is the background for this study?
Response: Our work was prompted by emerging concerns surrounding the potential nephrotoxic effects of hair-straightening products containing glyoxylic acid. This inquiry was instigated by a patient who experienced three repeated acute episodes of kidney injury in June 2020, April 2021, and July 2022, each occurring shortly after a hair-straightening procedure. Notably, these episodes resolved with hydration.
Upon examining the composition of the hair product used by the patient, which contained glyoxylic acid, and considering the patient's report of painful ulcer scalp during application and subsequent scalp scarring, we suspected a potential link between exposure to glyoxylic acid and kidney injury. Consulting with my colleague, Professor Emmanuel Letavenier, a specialist in crystalline nephropathy at Paris, confirmed this suspicion.
In summer 2023, cases series have been reported by an Israeli team (
Dr. Fangqun Yu[/caption]
Dr. Fangqun Yu PhD
Senior Research Faculty
Atmospheric Sciences Research Center University
Albany, State University of New York
Dr. Arshad Nair[/caption]
Dr. Arshad Arjunan Nair PhD
Postdoctoral Associate
Atmospheric Sciences Research Center
University at Albany, State University of New York